These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29588339)

  • 1. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
    Morrison K; Haag F; Ernst R; Iglarz M; Clozel M
    J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
    Morrison K; Ernst R; Hess P; Studer R; Clozel M
    J Pharmacol Exp Ther; 2010 Oct; 335(1):249-55. PubMed ID: 20660124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
    Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
    J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
    Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
    J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
    Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
    Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
    Kuwano K; Hashino A; Noda K; Kosugi K; Kuwabara K
    J Pharmacol Exp Ther; 2008 Sep; 326(3):691-9. PubMed ID: 18552131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
    Orie NN; Ledwozyw A; Williams DJ; Whittle BJ; Clapp LH
    Prostaglandins Other Lipid Mediat; 2013 Oct; 106():1-7. PubMed ID: 23872196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential properties of E prostanoid receptor-3 and thromboxane prostanoid receptor in activation by prostacyclin to evoke vasoconstrictor response in the mouse renal vasculature.
    Liu B; Zeng R; Guo T; Zhang Y; Leng J; Ge J; Yu G; Xu Y; Zhou Y
    FASEB J; 2020 Dec; 34(12):16105-16116. PubMed ID: 33047360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
    Kuwano K; Hashino A; Asaki T; Hamamoto T; Yamada T; Okubo K; Kuwabara K
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1181-8. PubMed ID: 17545310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased role of E prostanoid receptor-3 in prostacyclin-evoked contractile activity of spontaneously hypertensive rat mesenteric resistance arteries.
    Liu B; Zhan M; Zhang Y; Li H; Wu X; Zhuang F; Luo W; Zhou Y
    Sci Rep; 2017 Aug; 7(1):8927. PubMed ID: 28827689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
    Benyahia C; Boukais K; Gomez I; Silverstein A; Clapp L; Fabre A; Danel C; Leséche G; Longrois D; Norel X
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():48-55. PubMed ID: 23850788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.
    Orie NN; Clapp LH
    Eur J Pharmacol; 2011 Mar; 654(3):258-65. PubMed ID: 21185823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
    Kuwano K; Kosugi K; Fuchikami C; Funaki S
    Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension.
    Shen L; Patel JA; Norel X; Moledina S; Whittle BJ; von Kessler K; Sista P; Clapp LH
    Biochem Pharmacol; 2019 Aug; 166():242-252. PubMed ID: 31158340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of E-type prostaglandin receptor EP3 in the vasoconstrictor activity evoked by prostacyclin in thromboxane-prostanoid receptor deficient mice.
    Li Z; Zhang Y; Liu B; Luo W; Li H; Zhou Y
    Sci Rep; 2017 Feb; 7():42167. PubMed ID: 28165064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
    Menon AA; Sahay S; Braverman LE; Farber HW
    Lung; 2019 Dec; 197(6):761-768. PubMed ID: 31696306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.